**English version below**
Mach mit beim GSK Smart Manufacturing Graduate Programme - Deutschland, 2027: Hilf uns, Krankheiten gemeinsam vorzubeugen.
Erforderliche Ausbildung: Bachelor of Science (BSc); Master of Science (MSc) – Bachelor- oder Masterabschluss in einer naturwissenschaftlichen Fachrichtung (z. B. Ingenieurwissenschaften, Naturwissenschaften, technische oder biologische Wissenschaften) oder in einem verwandten Bereich mit Schwerpunkt auf Datenmanagement, digitalen Technologien, Change Management oder Projektmanagement. Abschluss bis August 2027.
Erforderliche Sprachen: Verhandlungssichere Deutsch- und Englischkenntnisse in Wort und Schrift
Standort: Marburg
Startdatum: September 2027
Bewerbungsfrist: Wir werden diese Stelle schließen, sobald wir genügend Bewerbungen haben. Bitte bewirb dich daher so bald wie möglich, damit deine Bewerbung berücksichtigt werden kann.
Online-Assessment-Center: Januar/Februar 2027
Schau dir an, was unsere Teilnehmer:innen des Graduate Programmes über ihre Erfahrungen berichten: https://www.youtube.com/watch?v=-ybQQr9HKg8 !
Bist du ein:e talentierte:r, engagierte:r Student:in oder Absolvent:in, der oder die darauf brennt, das Leben von Milliarden von Menschen positiv zu beeinflussen? Dann bewirb dich für das Smart Manufacturing Graduate Programme bei GSK und profitiere von maßgeschneiderter Ausbildung und Karriereentwicklung, die dir hilft, dich weiterzuentwickeln.
Wir produzieren hochwertige und zuverlässige Arzneimittel sowie Impfstoffe und stellen diese Patient:innen weltweit zur Verfügung.
Mit unserem Netzwerk aus 33 Produktionsstandorten haben wir allein 2025 beeindruckende 1,64 Milliarden Packungen Arzneimittel und 389 Millionen Impfdosen hergestellt – und so die Gesundheit von Millionen von Menschen positiv beeinflusst.
Unser Lieferkettenmanagement ist nicht nur zentral für unsere Abläufe, sondern auch entscheidend dafür, unsere Innovationen so schnell, effizient und effektiv wie möglich zu den Patienten zu bringen. Technologie verändert die Art und Weise, wie wir Medikamente und Impfstoffe herstellen, und ermöglicht es uns, die Geschwindigkeit, Qualität und den Umfang der Produktlieferung zu steigern.
Wir begrüßen Menschen mit unterschiedlichen Perspektiven sowie Fähigkeiten und Potenzial, die uns dabei unterstützen, komplexere Produkte herzustellen und die Möglichkeiten intelligenter Fertigungstechnologien wie Robotik, digitale Lösungen und künstliche Intelligenz zu nutzen, um für die Patienten zu liefern.
Starte deine Karriere, indem du dazu beiträgst, Arzneimittel und Impfstoffe weltweit zu den Patient:innen zu bringen.
In unserem zweijährigen Global Supply Chain Graduate Programme wendest du dein naturwissenschaftliches, ingenieurtechnisches oder digitales Wissen auf reale Herstellungsherausforderungen an und entwickelst dich durch Rotationen, Schulungen und Mentoring weiter.
Was dich erwartet:
Wichtige Programmmerkmale:
Werde Teil des GSK GSC Graduate Programmes und mache den ersten Schritt in Richtung einer erfüllenden Karriere, bei der deine Arbeit einen Unterschied für die Patienten:innen am Ende unserer Lieferkette macht.
Was wirst du tun?
Was du mitbringen solltest:
Was bieten wir dir?
Auf geht's!
Du findest Hinweise, Tipps und Anleitungen zu unserem Bewerbungsprozess auf unserer Website.
Du kannst außerdem unsere Early Careers FAQ-Seite mit Antworten auf häufige Fragen besuchen: Frequently asked questions | GSK
Erfahre mehr über den Bewerbungsprozess unter Application process | GSK
Nach Einreichung deiner Bewerbung wirst du gebeten, unsere GSK Digital Assessment zu absolvieren. Das GSK Digital Assessment gibt dir die Möglichkeit, deine Fähigkeiten durch spannende Übungen unter Beweis zu stellen, während wir Einblicke in deinen einzigartigen Arbeitsansatz gewinnen. Dies hilft uns, besser zu verstehen, wie deine Stärken, Verhaltensweisen und Fähigkeiten zu der Rolle passen und welchen positiven Beitrag du in unser Team einbringen könntest.
Top-Tipp #1: Speichere dir diese Stellenbeschreibung, um während des gesamten Prozesses darauf zurückgreifen zu können. Das wird dir wirklich helfen, dich auf die verschiedenen Phasen deiner Bewerbung vorzubereiten.
Mehr über GSK und unsere Karrieremöglichkeiten erfährst du hier: https://www.gsk.com/en-gb/careers/
Unsere Graduate Programme sind darauf ausgelegt, die Entwicklung von Absolvent:innen zu beschleunigen, die noch keine signifikante berufliche Erfahrung in dem Bereich haben, für den sie sich bewerben. Wenn du bereits umfassende Erfahrungen in einer professionellen Rolle in deinem Bereich gesammelt hast, kannst du dich zwar für dieses Programm bewerben, aber möglicherweise sind direkte Einstiegspositionen in unseren Unternehmen der beste Weg, um auf deinen vorhandenen Fähigkeiten und Kenntnissen aufzubauen und eine Karriere bei GSK zu entwickeln.
Bewirb dich jetzt!
Brauchst du Hilfe bei deiner Bewerbung?
Bitte schreib uns eine E-Mail unter [email protected] und lass uns wissen, wie wir dir helfen können oder schau in unseren FAQ-Bereich: Frequently asked questions | GSK.
Wenn du während des Bewerbungsprozesses aus irgendeinem Grund, auch im Zusammenhang mit einer Behinderung, Unterstützung oder Anpassungen benötigst, teile uns dies bitte unter [email protected] mit.
** ENGLISH VERSION**
Join the GSK Smart Manufacturing Graduate Programme – Germany, 2027: Help us get ahead of disease together.
Education required: Bachelor of Science/BSc; Master of Science/MSc - Bachelor’s or Master’s degree in a scientific discipline (such as Engineering, Science, Technical, Biological Sciences) or a related field, with a focus on data management, digital technologies, change management or project management. Graduation by August 2027.
Language requirement: Written and spoken fluency in German and English
Location: Marburg
Start date: September 2027
Application deadline: Applications are reviewed on a rolling basis, and this role will close once we have received enough applications. We recommend you apply as soon as possible.
Assessment Centre Date: January/February 2027
See what our graduate programme participants have to say about their experiences in our GSK Graduate Programmes https://www.youtube.com/watch?v=-ybQQr9HKg8 !
Are you a talented, driven student or graduate eager to make an impact on billions of lives? Join the Smart Manufacturing Graduate Programme at GSK and get ahead with tailored training and career development designed to help you grow.
We manufacture and supply reliable, high-quality medicines and vaccines to meet patients’ needs and drive our performance.
Our network of 33 medicines and vaccines manufacturing sites delivered 1.64 billion packs of medicines and 389 million vaccine doses in 2025 to help make a positive impact on the health of millions of people. Our supply chain is not just core to our operations; it’s vital to bringing our innovations to patients as quickly, efficiently and effectively as possible. Technology is transforming how we manufacture medicines and vaccines, enabling us to increase the speed, quality and scale of product supply.
We welcome people with diverse perspectives and the skills or potential to help us on our journey to make more complex products, harnessing the power of smart manufacturing technologies including robotics, digital solutions and artificial intelligence to deliver for patients.
Start your career by helping deliver medicines and vaccines to patients around the world.
On our two-year Global Supply Chain Graduate Programme, you’ll apply your scientific, engineering or digital knowledge to real manufacturing challenges while developing through rotations, training and mentoring.
What You’ll Experience:
Key Programme Features:
Join GSK’s GSC Graduate Programme and take the first step toward a rewarding career, where your work makes a difference to patients at the end of our supply chain.
What will you do?
What skills are we looking for?
What do we offer you?
Let’s do this!
You’ll find hints, tips and guidance on our recruitment process on our website.
You can also visit our Early Careers FAQ page for answers to common questions: Frequently asked questions | GSK
Learn more about the application process Application process | GSK
After submitting your application, you will be asked to complete our GSK Digital Assessment. The GSK Digital Assessment will give you the opportunity to demonstrate your skills through engaging exercises, while providing us with insights into your unique approach to work. This will help us better understand how your strengths, behaviors, and skills align with the role and the positive impact you could bring to our team.
Top tip #1: Save this job description. It will be your go-to guide throughout the application process and will help you feel prepared at every stage.
You can learn more about GSK and our careers here https://www.gsk.com/en-gb/careers/
Our Graduate Programmes are designed to accelerate the development of graduates who don’t have significant previous professional work experience in the area to which they are applying. If you’ve already developed substantial experience working in a professional role in your sector, while you would be able to apply for this programme, you may want to look at our direct entry roles as an alternate way to build on your existing skills and develop a career at GSK.
Apply now!
Need help with your application?
Please email us at [email protected] and let us know how we can help you or check our FAQ section Frequently asked questions | GSK.
If you require any support or adjustments during the recruitment process for any reason, including those related to a disability, please let us know at [email protected].
#GraduateProgramme
#EarlyCareers
#GPEMEA2027
#GPGermany2027
#ManufacturingSupplyChainGP
Skills
Germany Salary Range / Gehaltsbandbreiten Deutschland: EUR 40,650 to EUR 67,750For positions covered by collective bargaining, employment conditions and remuneration are determined by the applicable collective agreements for the chemical industry as well as internal policies. More detailed information on compensation will be provided during the recruitment process. Depending on the role and internal policies, the position may also be eligible for a bonus (if applicable and based on defined, non-discretionary criteria) and/or awards for exceptional performance (granted at the employer’s discretion). All benefits arising from the applicable collective bargaining agreement, such as holiday allowance and additional paid time off, will be provided in full, in accordance with that agreement and German law. Other benefits may also be offered, which may include health & wellbeing benefits, pension plan and paid parental leave & care of family member leave.Für tarifgebundene Positionen richten sich Beschäftigungsbedingungen und Vergütung nach den jeweils geltenden Tarifverträgen der chemischen Industrie sowie internen Richtlinien. Weiterführende Informationen zur Vergütung werden während des Einstellungsprozesses zur Verfügung gestellt. Abhängig von der Rolle und internen Richtlinien kann die Position u.a. auch einen Bonus und Awards für außergewöhnliche Leistungen beinhalten. Ergänzend zu den tarifvertraglichen Leistungen, wie z.B. Urlaubsgeld und zusätzlichen Freistellungstagen, können weitere Benefits angeboten werden, beispielsweise eine Altersvorsorge, Health & Wellbeing Benefits sowie bezahlte Elternzeit und Pflegezeit.Why GSK?
Uniting science, technology and talent to get ahead of disease together.
GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive. We get ahead of disease by preventing and treating it with innovation in specialty medicines and vaccines. We focus on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases – to impact health at scale.
People and patients around the world count on the medicines and vaccines we make, so we’re committed to creating an environment where our people can thrive and focus on what matters most. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we deliver for patients, shareholders and our people.
Should you require any adjustments to our process to assist you in demonstrating your strengths and capabilities contact us at [email protected] where you can also request a call.
Please note should your inquiry not relate to adjustments, we will not be able to support you through these channels. However, we have created a Recruitment FAQ guide. Click the link where you will find answers to multiple questions we receive.
GSK is an Equal Opportunity Employer. This ensures that all qualified applicants will receive equal consideration for employment without regard to ethnicity, colour, religion, sex (including pregnancy, gender identity, and sexual orientation), parental status, national origin, age, disability, genetic information (including family medical history), military service or any basis prohibited under federal, state or local law.
Important notice to Employment businesses/ Agencies
GSK does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact GSK's commercial and general procurement/human resources department to obtain prior written authorization before referring any candidates to GSK. The obtaining of prior written authorization is a condition precedent to any agreement (verbal or written) between the employment business/ agency and GSK. In the absence of such written authorization being obtained any actions undertaken by the employment business/agency shall be deemed to have been performed without the consent or contractual agreement of GSK. GSK shall therefore not be liable for any fees arising from such actions or any fees arising from any referrals by employment businesses/agencies in respect of the vacancies posted on this site.
Please note that if you are a US Licensed Healthcare Professional or Healthcare Professional as defined by the laws of the state issuing your license, GSK may be required to capture and report expenses GSK incurs, on your behalf, in the event you are afforded an interview for employment. This capture of applicable transfers of value is necessary to ensure GSK’s compliance to all federal and state US Transparency requirements. For more information, please visit the Centers for Medicare and Medicaid Services (CMS) website at https://openpaymentsdata.cms.gov/
GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1891
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.
The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.
The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.
GSK's Ris-Rez shows 61pc response rate in early lung cancer study. 1,856.00p. 13:24 19/10/26. Drugmaker GSK reported new early-stage global data for risvutatug rezetecan (Ris-Rez), an experimental cancer treatment being tested in patients with relapsed small-cell lung cancer. 10,747.73. 5,853.07. 5,792.15. 24,009.43. 13:23 19/10/26. In a phase Ib study, GSK said the drug produced a 61% response rate at the higher 8mg/kg dose, compared with 32% at 6mg/kg. GSK said the results, which will be presented at the ESMO 2026 congress in Madrid, support using the 8mg/kg dose in its ongoing global phase III trial. The FTSE 100-listed company said the treatment's side-effect profile was manageable, with most issues linked to blood-related conditions. More serious side effects occurred in 42% of patients at the higher dose and 15% at the lower dose. One case of interstitial lung disease was reported across 50 patients. GSK's Hesham Abdullah said: "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options." As of 0905 BST, GSK shares were up 0.16% at 1,865.50p. Reporting by Iain Gilbert at Sharecast.com
GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.